Denmark equities were lower at the close on Thursday, as losses in the Copenhagen Real Estate, OMX Copenhagen Personal & Household Goods PI and Copenhagen Health Care sectors led shares lower. At the ...

Denmark stocks were lower after the close on Thursday, as losses in the Real Estate, Personal & Household Goods and ...

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Genmab A/S logged a -1.6% change during today's morning session, and is now trading at a price of $22.1 per share. The S&P ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...